logo
Plus   Neg
Share
Email

Jazz Pharma Submits MAA To European Medicines Agency For Solriamfetol

Jazz Pharmaceuticals plc (JAZZ) announced Friday the submission of a Marketing Authorization Application or MAA to the European Medicines Agency for solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. It is for the treatment to improve wakefulness and reduce excessive daytime sleepiness or EDS in adult patients with narcolepsy (with or without cataplexy) or obstructive sleep apnea or OSA.

Jazz said it has studied solriamfetol extensively via the Treatment of OSA and Narcolepsy Excessive Sleepiness (TONES) Phase 3 program, which was comprised of four studies.

Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) in development for treatment of EDS in adult patients with narcolepsy, OSA, and Parkinson's disease. In 2014, Jazz Pharmaceuticals acquired a license to develop and commercialize solriamfetol from Aerial Biopharma.

Jazz Pharmaceuticals has worldwide development, manufacturing, and commercialization rights to solriamfetol, excluding certain jurisdictions in Asia. SK Biopharmaceuticals, the discoverer of the compound, maintains rights in 12 Asian markets, including Korea, China and Japan.

Solriamfetol has orphan drug designation in the United States for narcolepsy. In March 2018, Jazz announced that the U.S. Food and Drug Administration accepted for filing with standard review the company's New Drug Application or NDA seeking marketing approval for solriamfetol for the treatment of ES in adult patients with narcolepsy or OSA. The Prescription Drug User Fee Act (PDUFA) goal date for an FDA decision is December 20, 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Nordstrom Inc. (JWN) slipped 10 percent in extended hours on Thursday after the department store chain's full-year revenue outlook fell short of Street estimates. Seattle-based Nordstrom's third-quarter profit dropped to $67 million or $0.39 per share from $114 million or $0.67 per share... Shares of Nvidia Corp. (NVDA) plunged 16% in extended session on Thursday after chip designer's third-quarter revenues and fourth quarter outlook fell short of Wall Street estimates. Santa Clara, California-based Nvidia's third-quarter profit surged to $1.23 billion or $1.97 per share from $838 million... Retail giant Walmart Inc. on Thursday reported a 2 percent decrease in profit for the third quarter from last year as higher revenues were offset by one-time charges. However, adjusted earnings per share beat analysts' expectations, while revenue missed estimates. Looking ahead, the company lowered its outlook for fiscal 2019 reported earnings, but raised its outlook for adjusted earnings.
Follow RTT